Given the fact that daratumumab harbored AML-specific anti-leukemic activity, which was predominantly induced through microenvironment-mediated effects, we next asked whether CD38 expression on AML cells is influenced by microenvironmental cues and if the anti-leukemic activity of daratumumab depends on CD38 expression levels. The gene discussed is CD38; the disease is acute myeloid leukemia.